US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SDEV $3.94 ▲+0.00% SKHY $195.02 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00% INTC $116.19 ▲+0.00%
FinancialContent

Articles published by Neurogene

News headline image
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene
Via Business Wire
Tickers NGNE